SynthesisBMJ (Clinical research ed.)2025
Targeted therapy in advanced
Synthesis in BMJ (Clinical research ed.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrated Evaluation of Survival, Surgical Conversion, and Toxicity for Induction Therapy in Initially Unresectable Colorectal Liver Metastases: An Individual Patient Data Network Meta-analysis.Annals of surgical oncology · 2026Article
- Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways.Biomedicines · 2026Review
- Loss of GGT6 promotes colorectal cancer progression and correlates with poor prognosis: a study based on multi-database mining and functional validation.Translational cancer research · 2026Article
- Review
- Molecularly informed preoperative and response-adapted management of colorectal cancer: evidence, decision boundaries, and emerging directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the individual and comparative efficacy and safety of targeted therapy based strategies in advanced
designSystematic review and network meta-analysis. DATA SOURCES: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov from inception to 31 May 2025, and international conference proceedings. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Clinical trials and multicentre, real world studies investigating the efficacy and safety of targeted therapies for advanced DATA SYNTHESIS: The primary endpoint was overall survival in the first line and second or later line settings. Secondary endpoints included progression-free survival, objective response rate, disease control rate, and grade ≥3 adverse events. Single arm meta-analysis, pairwise meta-analysis, and network meta-analysis were performed to pool hazard ratios with 95% credible intervals (CrIs) for overall survival and progression-free survival, and odds ratios with 95% CrIs for objective response rate, disease control rate, and adverse events. The rankogram and surface under the cumulative ranking curve (SUCRA) evaluated the relative superiority of regimens in the network meta-analysis.
results60 studies involving 4633 patients with advanced
conclusionsFor initial treatment of advanced SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420250653959.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.